Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/54101
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJackowski, L.-
dc.contributor.authorStocks, N.-
dc.contributor.authorRowett, D.-
dc.date.issued2008-
dc.identifier.citationAustralian Family Physician, 2008; 37(9):721-726-
dc.identifier.issn0300-8495-
dc.identifier.urihttp://hdl.handle.net/2440/54101-
dc.description.abstractClopidogrel and aspirin both inhibit platelet aggregation, but have differing mechanisms of action that are additive in terms of antithrombotic function. The additive antithrombotic effect of aspirin and clopidogrel combination therapy provides additional clinical benefit compared to monotherapy in some circumstances, but the risk of major bleeding with combination therapy is greater than with either agent alone. (author abstract)-
dc.description.statementofresponsibilityJackowski, L; Stocks, N and Rowett, D-
dc.language.isoen-
dc.publisherRoyal Australian College of General Practitioners-
dc.source.urihttp://www.racgp.org.au/afp/200809/26759-
dc.subjectHumans-
dc.subjectThrombosis-
dc.subjectAspirin-
dc.subjectTiclopidine-
dc.subjectPlatelet Aggregation Inhibitors-
dc.subjectDrug Therapy, Combination-
dc.subjectClopidogrel-
dc.titleReducing the risk of adverse thrombotic events - The role of aspirin and clopidogrel-
dc.typeJournal article-
pubs.publication-statusPublished-
dc.identifier.orcidStocks, N. [0000-0002-9018-0361]-
Appears in Collections:Aurora harvest
General Practice publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.